TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Upgraded by Zacks Research

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by Zacks Research to a “hold” rating in a research report issued on Thursday, Zacks reports.

Several other brokerages also recently issued reports on TLSI. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Lake Street Capital dropped their price objective on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Finally, HC Wainwright started coverage on shares of TriSalus Life Sciences in a research note on Wednesday. They set a “buy” rating and a $11.00 target price for the company. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.67.

TriSalus Life Sciences Stock Down 0.9%

Shares of TriSalus Life Sciences stock opened at $4.66 on Thursday. The stock has a market capitalization of $286.96 million, a price-to-earnings ratio of -3.58 and a beta of 0.44. TriSalus Life Sciences has a twelve month low of $2.20 and a twelve month high of $7.95. The company has a current ratio of 5.35, a quick ratio of 4.97 and a debt-to-equity ratio of 5.05. The business’s 50 day simple moving average is $4.75 and its 200-day simple moving average is $4.33.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). The company had revenue of $11.41 million for the quarter, compared to analyst estimates of $10.27 million. Equities research analysts forecast that TriSalus Life Sciences will post -0.31 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Cura Wealth Advisors LLC bought a new stake in shares of TriSalus Life Sciences during the second quarter valued at about $36,000. JPMorgan Chase & Co. lifted its holdings in TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in TriSalus Life Sciences in the 2nd quarter valued at about $47,000. Invesco Ltd. bought a new position in TriSalus Life Sciences in the 4th quarter valued at about $72,000. Finally, Abel Hall LLC bought a new position in TriSalus Life Sciences in the 4th quarter valued at about $73,000. Institutional investors own 2.58% of the company’s stock.

More TriSalus Life Sciences News

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and an $11.00 price target, implying approximately 135.5% upside from the referenced $4.67 share price. The recommendation provides new analyst visibility and supports the bullish case for TLSI. HC Wainwright initiates coverage of TriSalus Life Sciences with a Buy rating
• Positive Sentiment: HC Wainwright’s forecasts point to improving long-term profitability. The firm estimates EPS of $0.09 in fiscal 2028, $0.57 in 2029 and $1.02 in 2030, suggesting expectations for substantial earnings growth as TriSalus expands its business.
• Neutral Sentiment: The analyst still expects losses through fiscal 2027, including EPS of negative $0.31 for 2026 and negative $0.28 for 2027. Quarterly loss estimates improve from negative $0.12 in the third quarter of 2026 to negative $0.02 in the fourth quarter of 2027, indicating gradual progress but continued reliance on execution and financing before profitability.
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 10, unchanged from the prior period. This indicates no measurable short-squeeze setup, but also no significant disclosed bearish short positioning.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.